Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc. provides laboratory services spanning diagnostics and drug development laboratory capabilities for doctors, hospitals, pharmaceutical companies, researchers and patients. News about LH commonly covers earnings releases and guidance, dividend declarations, specialty and companion diagnostics, oncology testing, drug-screening products, and collaborations that expand access to advanced laboratory services.
Company updates also address Labcorp's Diagnostics Laboratories and Biopharma Laboratory Services activities, including FDA-cleared or FDA-approved tests, pediatric diagnostics development, real-world data platforms, digital pathology and AI-enabled laboratory operations. Recurring announcements connect Labcorp's national diagnostic infrastructure with health systems, biopharmaceutical customers and technology partners.
Labcorp (NYSE: LH) launched MyLabcorp™, an AI-powered mobile app that helps consumers understand lab results and track health trends over time. The HIPAA-compliant app integrates Labcorp test results, OpenAI-powered explanations, and clinically reviewed educational content in a secure, personalized experience.
Users can review trends, chat with an AI assistant, access health education, schedule appointments, shop for tests, and manage billing. According to Labcorp, MyLabcorp is now available in the Apple App Store and Google Play Store, with additional features planned.
Labcorp (NYSE: LH) announced an expanded collaboration with Epic to offer Labcorp's full test menu through Epic's Aura platform, a unified system for ordering and receiving lab results.
The integration aims to reduce IT complexity, streamline lab ordering within Epic workflows, and expand access to advanced genetic and specialty diagnostics for hospitals and health systems nationwide.
Knoa Pharma (V) began operations on May 1, 2026 as a public health–focused pharmaceutical company wholly owned by the not‑for‑profit Knoa Foundation (a 501(c)(4)).
The company will manufacture existing medicines, including opioid analgesics, under a strict operating injunction with independent monitoring, will not promote opioid products, and will use value generated to fund opioid abatement and no‑profit access to overdose reversal and OUD treatments.
Labcorp (NYSE: LH) reported Q1 2026 revenue of $3.54B (up 5.8%) and diluted EPS of $3.35 (up 32.8%). Adjusted EPS was $4.25 (up 10.6%). Operating income rose to $380.8M; operating margin improved 100 bps. Free cash flow turned positive to $70.5M. Labcorp raised 2026 enterprise revenue guidance to +5.0%–6.1% and adjusted EPS to $17.70–$18.35 (midpoint $18.03).
The company cited acquisitions, diagnostics and biopharma growth, technology collaborations, $202.2M acquisitions, $98.0M buybacks, and a $0.72 quarterly dividend.
Labcorp (NYSE: LH) announced nationwide availability of Agilent's PD-L1 IHC 22C3 pharmDx on April 22, 2026, the only FDA‑approved companion diagnostic to identify patients with platinum‑resistant ovarian cancer eligible for Merck's KEYTRUDA therapies.
Labcorp joined Agilent's Early Validation Program to prepare standardized training and rapid rollout following the FDA's February approvals of KEYTRUDA and KEYTRUDA QLEX alongside the diagnostic.
Labcorp (NYSE: LH) launched the Labcorp Fentanyl Urine Visual Test, the first FDA-cleared rapid fentanyl urine test of its kind manufactured in the United States. The test delivers results in 10 minutes, detects norfentanyl with up to a 48-hour window, and is for CLIA-certified professional use.
Results are intended as preliminary screening and should be confirmed by laboratory methods. The test is available through Labcorp Point of Care (formerly MEDTOX Diagnostics), with product branding transitioning during 2026.
Labcorp (NYSE: LH) launched an AI-powered real-world data platform with AWS and Datavant to speed Alzheimer's research, using deidentified laboratory, genomic and claims data. The platform aims to compress months of data preparation into minutes, completes initial validation in spring 2026, and will expand through 2026 to additional disease areas.
It supports cohort identification, treatment-effectiveness analysis, and trial recruitment using Amazon Bedrock and SageMaker and privacy-preserving connectivity.
Labcorp (NYSE: LH) and Children's Hospital of Philadelphia announced a strategic collaboration on April 13, 2026 to speed discovery, development and national availability of specialized pediatric diagnostics.
The partnership creates a joint pediatric diagnostics innovation pipeline to develop age-appropriate tests across oncology, metabolic disease, autoimmune conditions and rare disorders and to expand nationwide access through Labcorp's laboratory network.
Labcorp (NYSE: LH) announced a quarterly cash dividend of $0.72 per share on April 9, 2026. The dividend is payable on June 11, 2026 to holders of record at the close of business on May 29, 2026.
This returns cash to shareholders and sets clear payment and record dates for investors.
Labcorp (NYSE: LH) will report first-quarter 2026 financial results before the market opens on April 30, 2026. A live webcast will begin at 9:00 a.m. ET the same day to discuss results. The earnings release and financial information will be posted on the investor relations website.
A replay will be posted approximately two hours after the live event and will remain available for one year on the site's News & Events section.